Business Daily from THE HINDU group of publications
Tuesday, Nov 11, 2008
ePaper | Mobile/PDA Version | Audio | Blogs
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Announcements
Lupin to sell cardiac drug

Mumbai, Nov. 10

Drug-maker Lupin Ltd has got the regulatory approval to launch a generic version of heart-rate lowering medicine Ivabradine in India. Sold under the brand name Ivabrad, the drug is being distributed by Lupin following its alliance with Chandigarh-based drug-maker Ind-Swift, who had developed the chemically similar, or generic version of Ivabradine, a Lupin spokesperson told Business Line. Details on the financial nature of the agreement were not divulged. Lupin's cardiovascular drugs segment has grown from about Rs 130 crore in fiscal 2006-07 to over Rs 175 crores in fiscal 2007-08, a note from Lupin said. - Our Bureau

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Lupin to sell cardiac drug

Glenmark Generics drug in US
Binani Ind plans buyback
East Coast Energy secures nod for Rs 600-cr jetty
Monorail project: Challenge for L&T
L&T consortium wins Mumbai monorail deal
MMTC bags Capexil award
McNally Bharat has 87% stake in McNally Sayaji
RIL arm may take 67% stake in KG Gas Network
Delphi Corp to invest Rs 250 cr near Chennai
Aries Agro starts new unit in Lucknow
RHW Hotel expanding presence
Bharat Forge, Alstom to form two joint ventures
Punj Lloyd, Dayim eye infra projects in Saudi Arabia
Murugappa group plans infrastructure biz entry
‘We’ve spooked ourselves into thinking there is a slowdown’
CESC plans Rs 2,000-cr investment to revive distribution network




eWorld
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line